Diagnostic Work-Up and Management of Pulmonary Hypertension
Begin with echocardiography as your first-line diagnostic test when PH is suspected, followed by a systematic algorithmic approach to identify the specific PH group, with right heart catheterization required for definitive diagnosis before initiating any PAH-specific therapy 1.
Initial Diagnostic Algorithm
Step 1: Echocardiographic Screening
When a patient presents with symptoms suggestive of PH (exertional dyspnea, fatigue, syncope, chest discomfort), obtain transthoracic echocardiography immediately 1. Use the estimated right ventricular systolic pressure (RVSP) to stratify probability:
- RVSP >45 mmHg warrants comprehensive PH work-up 2
- High or intermediate echocardiographic probability → proceed with full evaluation
- Low probability → consider alternative diagnoses and follow-up
Step 2: Mandatory Initial Testing Battery
All patients with high/intermediate probability PH require 1, 2:
Laboratory studies:
- CBC, comprehensive metabolic panel
- Liver function tests (screen for porto-pulmonary hypertension)
- Thyroid function tests
- NT-proBNP or BNP
- HIV serology
- Hepatitis panel
- Autoimmune antibody panel (ANA, anti-Scl-70, anti-centromere, anti-RNP, anti-SSA, anti-SSB)
- Hypercoagulable panel when indicated
Imaging and functional studies:
- ECG and chest radiograph
- Pulmonary function tests with DLCO (Class I recommendation) 1
- Arterial blood gases
- Six-minute walk test
- High-resolution CT chest (Class IIa recommendation) 1
- Abdominal ultrasound to screen for portal hypertension 1
Step 3: Distinguish PH Groups
Critical decision point: Determine if left heart disease (Group 2) or lung disease (Group 3) explains the PH 1:
- Review clinical history, symptoms, risk factors
- Analyze PFTs, chest imaging, arterial blood gases
- If Group 2/3 confirmed → treat underlying disease
- If severe PH or RV dysfunction present despite Group 2/3 disease → refer to PH expert center
Step 4: V/Q Scan - The Pivotal Test
If Group 2/3 PH excluded, perform ventilation/perfusion lung scan (Class I recommendation) 1:
Multiple segmental perfusion defects present:
- Suspect CTEPH (Group 4)
- Proceed to CT pulmonary angiography (Class I) 1
- Refer to CTEPH center for pulmonary angiography and surgical evaluation
- Do not rely on CT angiography alone - it can miss CTEPH 1
Normal or subsegmental patchy defects:
- Suspect PAH (Group 1) or Group 5 conditions
- Proceed to PAH-specific work-up
Step 5: Right Heart Catheterization - Mandatory Before Treatment
Never initiate PAH-specific therapy without RHC confirmation 3. RHC is required to:
- Confirm diagnosis: mPAP ≥20 mmHg (updated threshold), PAWP ≤15 mmHg, PVR >2 Wood units 4
- Assess disease severity
- Perform vasoreactivity testing in selected cases
- Guide initial risk stratification
Common pitfall: Only 7% of patients receiving calcium channel blockers for PAH actually met vasoreactivity criteria in real-world practice 5. This underscores why empiric therapy without proper hemodynamic assessment is dangerous.
Management Strategy
Risk Stratification at Diagnosis
Use comprehensive risk assessment incorporating multiple parameters 4:
- WHO functional class
- Six-minute walk distance
- NT-proBNP levels
- Hemodynamic parameters from RHC
- Presence of pericardial effusion or RV dysfunction
Classify patients as low, intermediate-low, intermediate-high, or high risk to guide treatment intensity.
Initial Treatment Approach for PAH (Group 1)
Low or intermediate risk patients:
- Initiate dual oral combination therapy immediately with phosphodiesterase-5 inhibitor + endothelin receptor antagonist 4
- This represents the current standard of care based on recent guidelines
High-risk patients:
- Consider initial triple combination therapy adding prostacyclin analogues to dual oral therapy 4
- Parenteral prostanoids are specifically indicated for advanced PAH 6
Vasoreactive patients (rare):
- Only use calcium channel blockers if acute vasoreactivity testing during RHC demonstrates appropriate response
- This applies to <10% of PAH patients
CTEPH-Specific Management
All CTEPH patients must be evaluated at specialized CTEPH centers 4 for:
- Pulmonary endarterectomy (curative surgical option)
- Balloon pulmonary angioplasty
- Medical therapy with riociguat or other agents
Follow-Up Monitoring
Perform regular reassessment using simplified 3-parameter model 4:
- WHO functional class
- NT-proBNP
- Six-minute walk distance
Consider repeat RHC during follow-up in patients at intermediate-low, intermediate-high, or high risk when therapeutic consequences are expected (conditional recommendation) 7.
Novel Therapies
For PAH patients already on treatment who remain at intermediate or high risk:
- Add sotatercept (activin signaling inhibitor) - strong recommendation based on high-certainty RCT evidence 7
- Must be managed in PH centers with regular monitoring for safety and efficacy
Critical Pitfalls to Avoid
- Never start PAH-specific drugs without RHC confirmation - this is unsafe and not guideline-concordant 3
- Do not miss CTEPH - always perform V/Q scan, as CT alone is insufficient 1
- Avoid calcium channel blockers without documented vasoreactivity - only 7% of real-world patients actually qualified 5
- Do not delay referral to PH expert centers - diagnostic delays remain a major problem contributing to poor outcomes 5
- Lung biopsy is contraindicated in PAH (Class III recommendation) 1
When to Refer to PH Expert Center
Immediate referral indicated for 1:
- Confirmed or suspected PAH after excluding Groups 2 and 3
- Any CTEPH diagnosis or suspicion
- Group 2,3, or 5 PH with severe hemodynamics (PVR >5 Wood units) 4
- Signs of severe PH or RV dysfunction despite treating underlying disease